{"name":"Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux","slug":"groupe-d-etude-sur-le-risque-d-exposition-des-soignants-aux-agents-infectieux","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Genvoya","genericName":"Genvoya","slug":"genvoya","indication":"Other","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"raltegravir (Isentress)","genericName":"raltegravir (Isentress)","slug":"raltegravir-isentress","indication":"HIV-1 infection in treatment-naïve and treatment-experienced adults","status":"phase_3"}]}],"pipeline":[{"name":"Genvoya","genericName":"Genvoya","slug":"genvoya","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"raltegravir (Isentress)","genericName":"raltegravir (Isentress)","slug":"raltegravir-isentress","phase":"phase_3","mechanism":"Raltegravir inhibits HIV integrase, preventing the virus from integrating its genetic material into the host cell's DNA.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced adults","HIV-1 infection in pediatric patients"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":1,"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}